Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Hematopoietic Stem Cell Transplantation Market Snapshot (2023 to 2033)

The global hematopoietic stem cell transplantation market garnered a market value of US$ 7 Billion in 2023 and is expected to accumulate a market value of US$ 15 Billion by registering a CAGR of 8% in the forecast period 2023 to 2033. Because of the rising frequency of leukemia and lymphoma, the worldwide hematopoietic stem cell transplantation industry is predicted to rise significantly over the forecast period.

According to the Centers for Disease Control and Prevention (CDC), about 45,360 persons were diagnosed with leukemia in the United States in 2013, resulting in 23,549 deaths (13,625 men and 9,924 women). In accordance with the same source, men are more likely than women to have the illness. Leukemia contributes to approximately 3% of novel cancer cases.

Data Points Key Statistics
Expected Market Value (2023) US$ 7 Billion
Anticipated Forecast Value (2033) US$ 15 Billion
Projected Growth Rate (2023 to 2033) 8% CAGR

Hematopoietic stem cell transplantation is a process in which multipotent hematopoietic stem cells are transferred into the patient from peripheral blood cells, bone marrow, or umbilical cord blood.

Lymphoma (Hodgkin and non-Hodgkin), leukemia, multiple myeloma, thalassemia, sickle cell anemia, and osteoporosis are all widely treated by hematopoietic stem cell transplantation. It has two transplantation sources: autologous (using stem cells from the patient's own body) and allogeneic (using stem cells from a donor's body).

According to the World Health Organization (WHO), approximately 50,000 hematopoietic stem cell transplantation surgeries are carried out globally each year, with this figure anticipated to rise in the coming years. During the projected period, factors such as the increasing frequency of hematopoietic stem cell transplants are likely to drive market expansion.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Hematopoietic Stem Cell Transplantation Demand Analysis (2018 to 2022) Vs Market Outlook (2023 to 2033)

The global demand for hematopoietic stem cell transplantation is projected to increase at a CAGR of 8% during the forecast period between 2023 to 2032, reaching a total of US$ 15 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 6%.

The worldwide hematopoietic stem cell transplantation market is going to expand rapidly due to an increase in the frequency of hematological illnesses, an increase in transplant success rates, and growth in the world's aging population. According to a Scientific America study report, global transplantation rates have grown from 50,000 HSC transplants per year in 2012 to 75,000 HSC transplants per year in 2015. However, high transplantation costs and a shortage of financing for organizations such as the Worldwide Network for Blood and Marrow Transplantation (WBMT) are projected to limit the worldwide hematopoietic stem cell transplantation industry over the projection period.

Which are Some Prominent Drivers of Hematopoietic Stem Cell Transplantation Market?

The rising Frequency of Leukaemia and Lymphoma is Propelling the Worldwide Hematopoietic Stem Cell Transplantation Market Forward

During the projected period, the rising frequency of leukemia and lymphoma is likely to boost the hematopoietic stem cell transplantation market.

According to the Leukemia and Lymphoma Society's 2019 report, an estimated 176,200 people in the United States were diagnosed with leukemia, lymphoma, or myeloma, and roughly 1,399,180 people were living with leukemia, lymphoma, or myeloma. The rising incidence rate is predicted to fuel demand for hematopoietic stem cell transplantation, driving the hematopoietic stem cell transplantation (HSCT) industry forward.

As claimed by, the World Cancer Research Fund 2018 study, one-third of cancer cases (globally) are caused by a lack of physical exercise, obesity, and/or poor nutrition in economically developed nations such as the United States and Europe. Furthermore, 90% of leukemia starts in middle age and worsens with age.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Which are the Trough Areas faced by the Hematopoietic Stem Cell Transplantation Market?

Adverse Impacts of Hematopoietic Stem Cell Transplantation to Stifle Market Growth

The adverse impacts of hematopoietic stem cell transplantation on organs and body parts such as the gastrointestinal tract, mouth, heart, and lungs associated with the conditioning regimen and others, as well as the serious complication of graft vs. host disease, are expected to slow the market's growth.

Graft-versus-host disease (GVHD) is a consequence of both normal allogeneic and reduced-intensity allogeneic stem cell transplants in which the graft perceives the patient's healthy cells (the host) as foreign and attacks and damages them. A tight HLA match between the donor and the patient reduces but does not eliminate, the risk of GVHD. Graft-versus-host disease has three severity levels: mild, moderate, and severe. In certain situations, it can be fatal.

Region-Wise Insights

How will Hematopoietic Stem Cell Transplantation Market Demand progress in the Asia Pacific?

Increased Frequency of Blood Cancer Diseases for Widening Profit Margins

Asia-Pacific is predicted to expand during the projected timeline of 2023 to 2033 due to the increased frequency of blood cancer diseases and an increase in the number of generic manufacturers in this region.

The expansion of healthcare infrastructure and an aging population will drive the market's growth rate in this area. As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 7.5% in the assessment period 2023 to 2033.

How attractive are Growth Prospects for Hematopoietic Stem Cell Transplantation in North America?

Rising leukemia incidences to Drive Market Growth in the Region

Over the projected period, North America is likely to lead the entire hematopoietic stem cell transplantation market. Rising leukemia incidences and increased investment in research and development by the public and commercial sectors are the major determinants for the industry in the North American region. For example, according to data provided by the Canadian Cancer Society in May 2022, 6,700 Canadians will be diagnosed with leukemia in 2022. It was also estimated that 4,000 males will be diagnosed with leukemia, and around 2,700 women will be afflicted with leukemia, with 1,300 dying as a result. Stem cell transplants aid in the treatment of leukemia by enabling the body to replenish damaged blood cells with healthy ones.

Hematopoietic stem cells aid in the treatment of leukemia by allowing the body to replace damaged blood cells with healthy blood cells. Stem cells can differentiate into a variety of different types of cells. As a result, rising leukemia incidences are likely to drive demand for hematopoietic stem cell transplantation, fuelling market growth throughout the forecast period.

Prominent factors contributing to the expansion of the hematopoietic stem cell transplantation industry in the future include key product releases, high concentration of market participants or manufacturer's presence, acquisition & alliances among significant players, and expanding the United States. For example, according to the Leukemia and Lymphoma Society's facts and Statistics, around 90,390 persons in the United States were predicted to be diagnosed with lymphoma in 2021. (8,830 Hodgkin Lymphoma cases and 81,560 cases of Non-Hodgkin Lymphoma). As a result, North America is expected to grow at a CAGR of 7.9% in the assessment period 2023 to 2033.

What are the Prominent Factors Shaping the Growth of Hematopoietic Stem Cell Transplantation in Europe?

Overall Increase in Transplant Success Rates fuelling the Market Growth

During the projection period, Europe is expected to lead the worldwide market. The region's supremacy is linked to an overall increase in transplant success rates, simple technical applications, and high population affluence. Thus, owing to the aforementioned reasons, Europe is expected to grow at a CAGR of 7.6% in the forecast period 2023 to 2033.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

Which is the Most Preferred Transplant Type in the Hematopoietic Stem Cell Transplantation Market?

The Autologous Segment to enhance Sales Prospects

The worldwide hematopoietic stem cell transplantation industry is categorized into two categories: allogeneic and autologous. Despite accounting for a significant portion of the HSCT business in 2021, autologous is an important and sophisticated medical procedure employed in the treatment of a variety of malignant and non-malignant illnesses.

Which is the Most Lucrative Application Segment Type in the Hematopoietic Stem Cell Transplantation Market?

The Bone Marrow Transplant Segment is Predicted to Gain Traction

A bone marrow transplant is a surgery that involves injecting healthy blood-forming stem cells into the body to replace bone marrow that is not producing enough healthy blood cells. A stem cell transplant is another name for a bone marrow transplant. In individuals with malfunctioning or depleted bone marrow, a bone marrow transplant involves the introduction of healthy hematopoietic stem cells. This method is used to treat tumors that damage the bone marrow, such as leukemia, myeloma, lymphoma, and other blood and immune system illnesses.

Increased Research and Development efforts are likely to drive segment growth during the forecast period. For example, Gamida Cell Ltd. stated in October 2020 that the Phase 3 study of omidubicel, an innovative advanced cell therapy under development, is a potentially life-saving therapeutic option for patients in need of bone marrow transplant and fulfilled all three of its secondary goals.

Increased positive initiatives by the public and private sectors toward bone marrow transplants are expected to drive category expansion. For example, the QUINT founders gave around USD 16.0 million in September 2022 to create the QUINT bone marrow transplant center in Dubai. The great effectiveness and benefits of bone marrow transplant in treating acute myeloid leukemia are driving sector expansion.

Start-Ups for Hematopoietic Stem Cell Transplantation Market

Key start-up players in the hematopoietic stem cell transplantation are offering new and innovative product lines to consolidate their market presence, these aforementioned start-ups have left no stone unturned. Some specific instances of key hematopoietic stem cell transplantation start-ups are as follows:

  • Ankyra, a firm located in the United States, is developing Anchored Immunotherapy, a cytokine suppression-based immunotherapy. It boosts the effectiveness of cytokine immunotherapy and prolongs anti-tumor immunological activation of T-cells, natural killer (NK) cells, and meloids. The company is also working on a platform for administering immune stimulants to localize and maintain cytokines in tumor locations. Unlike systemic dosage, this technique benefits in reducing drug toxicity and improving non-target tissue safety. The company creates medication pipelines for solid tumors in people and animals.
  • OXvax, located in the United Kingdom, develops a dendritic cell (DC) immuno-oncology vaccination platform. It generates large amounts of CD141+XCR1 DC subset from induced pluripotent stem cells using a unique methodology (iPSC). This novel DC fraction is related to the uncommon myeloid cDC1 DC subset, which has superior tolerance and powerful anti-tumor response. The company's commercially available semi-allogeneic vaccinations cure intractable solid tumor malignancies.
  • Catamaran Bio is a firm established in the United States that provides TAILWIND, a patented technology package for engineering and manufacturing NK cells. To program NK cells, it uses synthetic biotechnology-enabled tumor microenvironment (TME) switches and the TcBuster transposon system. Furthermore, the suite employs non-viral cell engineering to produce cells with chimeric antigen receptor (CAR) design tailored for NK cells. The company offers CAR-NK cell treatment method development, cell engineering, growth, and cryopreservation for solid tumors.

Market Competition

Key players in the hematopoietic stem cell transplantation market are Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Sanofi, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio and Talaris Therapeutics.

Recent Developments:

  • In December 2022, despite missing the primary endpoint, Takeda's Phase 3 AURORA study shows that maribavir has a clinically meaningful and long-lasting effect on Cytomegalovirus (CMV) infection in hematopoietic stem cell transplant patients.
  • In October 2022, Regen BioPharma, Inc. announced the filing of a provisional patent application with the USPTO titled "Enhancement of T Cell Homing to Tumors through Augmentation of Chemokine Responsiveness and Activation Dependent Chemokine Secretion" with the US Patent and Trademark Office.
  • In November 2022, Lonza, a trusted partner in the pharmaceutical, biotech, and nutraceutical industries, introduced an innovative new capsule solution for enteric drug administration. The Capsugel® EnprotectTM capsule does not dissolve in the stomach and releases its contents only in the intestine. By eliminating the need for extra capsule coating or sealing, Capsugel® EnprotectTM capsules greatly simplify the medicinal product production process.
  • In November 2021, Taiga Biotechnologies, a cell-based immunotherapy company, announced today that the first site in Croatia has completed the site initiation session for the TBX-2400-01 clinical trial, a Phase 1/2 study to evaluate the safety and early efficacy of TBX-2400 in acute myeloid leukemia (AML) and myelofibrosis patients undergoing hematopoietic stem cell transplant (HSCT)

Report Scope

Report Attribute Details
Market Value in 2023 US$ 7 Billion
Market Value in 2033 US$ 15 Billion
Growth Rate CAGR of 8% from 2023 to 2032
Base Year for Estimation 2021
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US Billion and CAGR from 2023 to 2032
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • Transplant Type
  • Indication
  • Application
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa (MEA)
Key Countries Profiled
  • USA
  • Canada
  • Brazil
  • Mexico
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • China
  • Japan
  • South Korea
  • India
  • Malaysia
  • Singapore
  • Australia
  • New Zealand
  • GCC
  • South Africa
  • Israel
Key Companies Profiled
  • Pluristem Therapeutics Inc.
  • CellGenix GmbH
  • Regen Biopharma Inc.
  • Lonza Group
  • Sanofi
  • Taiga Biotechnologies, Inc.
  • Takeda Pharmaceutical Company Limited
  • Escape Therapeutics, Inc.
  • Bluebird Bio
  • Talaris Therapeutics
Customization Available Upon Request

Key Segments Profiled in the Hematopoietic Stem Cell Transplantation Market Industry Survey

By Transplant Type:

  • Allogeneic
  • Autologous

By Indication:

  • Acute Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma
  • Multiple Myeloma
  • Other Non-Malignant Disorders

By Application:

  • Bone Marrow Transplant
  • Peripheral Blood Stem Cells Transplant
  • Cord Blood Transplant

Hematopoietic Stem Cell Transplantation Market by Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa (MEA)

Frequently Asked Questions

What Role Does the Regulatory Landscape Play in the Market?

Changing rules have an impact on the market by assuring the safety and quality.

How is the Integration of Technology Influencing the Market?

Technological advancements are improving the accuracy and efficiency of transplantation.

What Trends are Shaping the Hematopoietic Stem Cell Transplantation Market?

Personalized therapy and breakthroughs in transplantation techniques.

What are the Key Insights in the Market?

The potential for treating numerous hematological illnesses is seeing increased usage.

What is the Current Market Capitalization of the Industry?

The market capitalization is projected to be around US$ 7 billion.

Table of Content

1. Executive Summary | Hematopoietic Stem Cell Transplantation Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Transplant Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Transplant Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Transplant Type, 2023 to 2033

        5.3.1. Allogeneic

        5.3.2. Autologous

    5.4. Y-o-Y Growth Trend Analysis By Transplant Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Transplant Type, 2023 to 2033

6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Indication, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication, 2023 to 2033

        6.3.1. Acute Myeloid Leukemia

        6.3.2. Acute Lymphoblastic Leukemia

        6.3.3. Hodgkin Lymphoma

        6.3.4. Non-Hodgkin Lymphoma

        6.3.5. Multiple Myeloma

        6.3.6. Other Non-Malignant Disorders

    6.4. Y-o-Y Growth Trend Analysis By Indication, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Indication, 2023 to 2033

7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2023 to 2033

        7.3.1. Bone Marrow Transplant

        7.3.2. Peripheral Blood Stem Cells Transplant

        7.3.3. Cord Blood Transplant

    7.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033

8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. Asia Pacific

        8.3.5. Middle East & Africa (MEA)

    8.4. Market Attractiveness Analysis By Region

9. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Transplant Type

        9.2.3. By Indication

        9.2.4. By Application

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Transplant Type

        9.3.3. By Indication

        9.3.4. By Application

    9.4. Key Takeaways

10. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Transplant Type

        10.2.3. By Indication

        10.2.4. By Application

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Transplant Type

        10.3.3. By Indication

        10.3.4. By Application

    10.4. Key Takeaways

11. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. UK

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Transplant Type

        11.2.3. By Indication

        11.2.4. By Application

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Transplant Type

        11.3.3. By Indication

        11.3.4. By Application

    11.4. Key Takeaways

12. Asia Pacific Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

            12.2.1.4. Singapore

            12.2.1.5. Thailand

            12.2.1.6. Indonesia

            12.2.1.7. Australia

            12.2.1.8. New Zealand

            12.2.1.9. Rest of Asia Pacific

        12.2.2. By Transplant Type

        12.2.3. By Indication

        12.2.4. By Application

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Transplant Type

        12.3.3. By Indication

        12.3.4. By Application

    12.4. Key Takeaways

13. MEA Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. GCC Countries

            13.2.1.2. South Africa

            13.2.1.3. Israel

            13.2.1.4. Rest of MEA

        13.2.2. By Transplant Type

        13.2.3. By Indication

        13.2.4. By Application

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Transplant Type

        13.3.3. By Indication

        13.3.4. By Application

    13.4. Key Takeaways

14. Key Countries Analysis

    14.1. USA

        14.1.1. Pricing Analysis

        14.1.2. Market Share Analysis, 2022

            14.1.2.1. By Transplant Type

            14.1.2.2. By Indication

            14.1.2.3. By Application

    14.2. Canada

        14.2.1. Pricing Analysis

        14.2.2. Market Share Analysis, 2022

            14.2.2.1. By Transplant Type

            14.2.2.2. By Indication

            14.2.2.3. By Application

    14.3. Brazil

        14.3.1. Pricing Analysis

        14.3.2. Market Share Analysis, 2022

            14.3.2.1. By Transplant Type

            14.3.2.2. By Indication

            14.3.2.3. By Application

    14.4. Mexico

        14.4.1. Pricing Analysis

        14.4.2. Market Share Analysis, 2022

            14.4.2.1. By Transplant Type

            14.4.2.2. By Indication

            14.4.2.3. By Application

    14.5. Germany

        14.5.1. Pricing Analysis

        14.5.2. Market Share Analysis, 2022

            14.5.2.1. By Transplant Type

            14.5.2.2. By Indication

            14.5.2.3. By Application

    14.6. UK

        14.6.1. Pricing Analysis

        14.6.2. Market Share Analysis, 2022

            14.6.2.1. By Transplant Type

            14.6.2.2. By Indication

            14.6.2.3. By Application

    14.7. France

        14.7.1. Pricing Analysis

        14.7.2. Market Share Analysis, 2022

            14.7.2.1. By Transplant Type

            14.7.2.2. By Indication

            14.7.2.3. By Application

    14.8. Spain

        14.8.1. Pricing Analysis

        14.8.2. Market Share Analysis, 2022

            14.8.2.1. By Transplant Type

            14.8.2.2. By Indication

            14.8.2.3. By Application

    14.9. Italy

        14.9.1. Pricing Analysis

        14.9.2. Market Share Analysis, 2022

            14.9.2.1. By Transplant Type

            14.9.2.2. By Indication

            14.9.2.3. By Application

    14.10. China

        14.10.1. Pricing Analysis

        14.10.2. Market Share Analysis, 2022

            14.10.2.1. By Transplant Type

            14.10.2.2. By Indication

            14.10.2.3. By Application

    14.11. Japan

        14.11.1. Pricing Analysis

        14.11.2. Market Share Analysis, 2022

            14.11.2.1. By Transplant Type

            14.11.2.2. By Indication

            14.11.2.3. By Application

    14.12. South Korea

        14.12.1. Pricing Analysis

        14.12.2. Market Share Analysis, 2022

            14.12.2.1. By Transplant Type

            14.12.2.2. By Indication

            14.12.2.3. By Application

    14.13. Singapore

        14.13.1. Pricing Analysis

        14.13.2. Market Share Analysis, 2022

            14.13.2.1. By Transplant Type

            14.13.2.2. By Indication

            14.13.2.3. By Application

    14.14. Thailand

        14.14.1. Pricing Analysis

        14.14.2. Market Share Analysis, 2022

            14.14.2.1. By Transplant Type

            14.14.2.2. By Indication

            14.14.2.3. By Application

    14.15. Indonesia

        14.15.1. Pricing Analysis

        14.15.2. Market Share Analysis, 2022

            14.15.2.1. By Transplant Type

            14.15.2.2. By Indication

            14.15.2.3. By Application

    14.16. Australia

        14.16.1. Pricing Analysis

        14.16.2. Market Share Analysis, 2022

            14.16.2.1. By Transplant Type

            14.16.2.2. By Indication

            14.16.2.3. By Application

    14.17. New Zealand

        14.17.1. Pricing Analysis

        14.17.2. Market Share Analysis, 2022

            14.17.2.1. By Transplant Type

            14.17.2.2. By Indication

            14.17.2.3. By Application

    14.18. GCC Countries

        14.18.1. Pricing Analysis

        14.18.2. Market Share Analysis, 2022

            14.18.2.1. By Transplant Type

            14.18.2.2. By Indication

            14.18.2.3. By Application

    14.19. South Africa

        14.19.1. Pricing Analysis

        14.19.2. Market Share Analysis, 2022

            14.19.2.1. By Transplant Type

            14.19.2.2. By Indication

            14.19.2.3. By Application

    14.20. Israel

        14.20.1. Pricing Analysis

        14.20.2. Market Share Analysis, 2022

            14.20.2.1. By Transplant Type

            14.20.2.2. By Indication

            14.20.2.3. By Application

15. Market Structure Analysis

    15.1. Competition Dashboard

    15.2. Competition Benchmarking

    15.3. Market Share Analysis of Top Players

        15.3.1. By Regional

        15.3.2. By Transplant Type

        15.3.3. By Indication

        15.3.4. By Application

16. Competition Analysis

    16.1. Competition Deep Dive

        16.1.1. Pluristem Therapeutics Inc.

            16.1.1.1. Overview

            16.1.1.2. Product Portfolio

            16.1.1.3. Profitability by Market Segments

            16.1.1.4. Sales Footprint

            16.1.1.5. Strategy Overview

                16.1.1.5.1. Marketing Strategy

        16.1.2. CellGenix GmbH

            16.1.2.1. Overview

            16.1.2.2. Product Portfolio

            16.1.2.3. Profitability by Market Segments

            16.1.2.4. Sales Footprint

            16.1.2.5. Strategy Overview

                16.1.2.5.1. Marketing Strategy

        16.1.3. Regen Biopharma Inc.

            16.1.3.1. Overview

            16.1.3.2. Product Portfolio

            16.1.3.3. Profitability by Market Segments

            16.1.3.4. Sales Footprint

            16.1.3.5. Strategy Overview

                16.1.3.5.1. Marketing Strategy

        16.1.4. Lonza Group

            16.1.4.1. Overview

            16.1.4.2. Product Portfolio

            16.1.4.3. Profitability by Market Segments

            16.1.4.4. Sales Footprint

            16.1.4.5. Strategy Overview

                16.1.4.5.1. Marketing Strategy

        16.1.5. Sanofi

            16.1.5.1. Overview

            16.1.5.2. Product Portfolio

            16.1.5.3. Profitability by Market Segments

            16.1.5.4. Sales Footprint

            16.1.5.5. Strategy Overview

                16.1.5.5.1. Marketing Strategy

        16.1.6. Taiga Biotechnologies, Inc.

            16.1.6.1. Overview

            16.1.6.2. Product Portfolio

            16.1.6.3. Profitability by Market Segments

            16.1.6.4. Sales Footprint

            16.1.6.5. Strategy Overview

                16.1.6.5.1. Marketing Strategy

        16.1.7. Takeda Pharmaceutical Company Limited

            16.1.7.1. Overview

            16.1.7.2. Product Portfolio

            16.1.7.3. Profitability by Market Segments

            16.1.7.4. Sales Footprint

            16.1.7.5. Strategy Overview

                16.1.7.5.1. Marketing Strategy

        16.1.8. Escape Therapeutics, Inc.

            16.1.8.1. Overview

            16.1.8.2. Product Portfolio

            16.1.8.3. Profitability by Market Segments

            16.1.8.4. Sales Footprint

            16.1.8.5. Strategy Overview

                16.1.8.5.1. Marketing Strategy

        16.1.9. Bluebird Bio

            16.1.9.1. Overview

            16.1.9.2. Product Portfolio

            16.1.9.3. Profitability by Market Segments

            16.1.9.4. Sales Footprint

            16.1.9.5. Strategy Overview

                16.1.9.5.1. Marketing Strategy

        16.1.10. Talaris Therapeutics

            16.1.10.1. Overview

            16.1.10.2. Product Portfolio

            16.1.10.3. Profitability by Market Segments

            16.1.10.4. Sales Footprint

            16.1.10.5. Strategy Overview

                16.1.10.5.1. Marketing Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

Recommendations

Healthcare

Stem Cell Therapy Market

Published : March 2024

Healthcare

Bone Marrow Transplant Market

Published : July 2023

Healthcare

Cell Line Development Services Market

Published : July 2023

Explore Healthcare Insights

View Reports

Hematopoietic Stem Cell Transplantation Market